#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malignant oligodendroglioma Aplastic anaemia Hypoxic-ischaemic encephalopathy Cortical dysplasia Glomerulonephritis membranoproliferative Autoimmune disorder Congenital nephrogenic diabetes insipidus Tourette's disorder Ductal adenocarcinoma of pancreas Arterial tortuosity syndrome Phenylketonuria Hypotransferrinaemia Polycythaemia vera Amyotrophic lateral sclerosis Mycobacterium abscessus infection More trials…

    Learn about Rare Diseases

    Hereditary angioedema with C1 esterase inhibitor deficiency – Basic Information Inclusion body myositis – Treatment IgA nephropathy – Trials in Disease Factor IX deficiency – Trials in Disease Friedreich’s ataxia – Life with Disease Rhabdomyosarcoma recurrent – Basic Information Optic glioma – Diagnostics Cystic fibrosis – Diagnostics Medulloblastoma recurrent Pemphigoid – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Siplizumab PALAZESTRANT Mitotane Tolu Balsam IMELASOMERAN Mavorixafor [18F]Alf-Nota-Octreotide Deferiprone Sphingomyelin (Egg) BNT327 Tofacitinib L-ALANINE Methoxyflurane Placebo Selinexor Sodium Citrate Anb032 Diclofenac ATTR-01 Tobevibart More therapies…

    Learn about Your Condition

    Connective tissue disorder Glucose tolerance impaired Crigler-Najjar syndrome Mantle cell lymphoma stage III Senile dementia Cancer pain Rett syndrome Drug use disorder Spinal cord injury cervical Prinzmetal angina Skin disorder Dementia with Lewy bodies Huntington's disease Primary myelofibrosis Pseudomyxoma peritonei More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Nervous System Diseases

  • A Study of Zanubrutinib for Patients with Anti-MAG Antibody Neuropathy Associated with Blood Disorders or Abnormal Protein in the Blood

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Marginal zone lymphoma
    • Waldenstrom’s macroglobulinaemia
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Zanubrutinib
    Italy

  • Long-term Safety Study of ORX750 for Patients with Narcolepsy and Idiopathic Hypersomnia Who Completed a Previous ORX750 Trial

    Recruiting

    4 1 1
    Investigated Drugs:
    • ORX750
    France Italy Spain

  • A Study of Emrusolmin Safety and Effectiveness in Adults with Multiple System Atrophy, a Brain and Nerve Disorder

    Recruiting

    2 1 1
    Investigated Diseases:
    • Multiple system atrophy
    Investigated Drugs:
    • Emrusolmin
    France Germany Italy Spain

  • A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • RO7268489
    • Ocrelizumab
    France Germany Hungary Italy Poland Portugal +1

  • A study testing Wharton’s jelly-derived mesenchymal stem cells with spinal cord stimulation for adults with chronic spinal cord injury

    Recruiting

    1 1 1
    Investigated Diseases:
    • Spinal cord injury
    Investigated Drugs:
    • ALLOGENEIC VIABLE WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELLS, EX-VIVO EXPANDED
    Spain

  • A Study Testing if Daily Tadalafil Improves Movement Symptoms in Patients with Early-Stage Parkinson’s Disease Who Have Not Yet Started Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Tadalafil
    The Netherlands
Previous Page
1 … 7 8 9 10 11 … 141
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!